SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes

被引：0
|
作者：
Davila, Esteban [1 ]
Mccormack, James [2 ]
机构：
[1] New York City Hlth Hosp Kings Cty, Dept Emergency Med, 451 Clarkson Ave, Brooklyn, NY 11203 USA
[2] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
来源：
ACADEMIC EMERGENCY MEDICINE | 2024年 / 31卷 / 04期
关键词：
diabetes; GLP-1 receptor agonist; metformin; SGLT-2; inhibitor;
D O I：
10.1111/acem.14895
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：408 / 411
页数：4
相关论文
共 50 条
  • [21] Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review
    Gonzalez-Gonzalez, Jose Gerardo
    Diaz Gonzalez-Colmenero, Alejandro
    Millan-Alanis, Juan Manuel
    Lytvyn, Lyubov
    Solis, Ricardo Cesar
    Mustafa, Reem A.
    Palmer, Suetonia C.
    Li, Sheyu
    Hao, Qiukui
    Alvarez-Villalobos, Neri Alejandro
    Vandvik, Per Olav
    Rodriguez-Gutierrez, Rene
    BMJ OPEN, 2021, 11 (07):
  • [22] SGLT-2 Inhibitors' and GLP-1 Receptor Agonists' Influence on Neuronal and Glial Damage in Experimental Stroke
    Murasheva, Anna
    Fuks, Oksana
    Timkina, Natalya
    Mikhailova, Arina
    Vlasov, Timur
    Samochernykh, Konstantin
    Karonova, Tatiana
    BIOMEDICINES, 2024, 12 (12)
  • [23] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Nagahisa, Taichi
    Saisho, Yoshifumi
    DIABETES THERAPY, 2019, 10 (05) : 1733 - 1752
  • [24] Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Rodriguez, Luis A.
    Finertie, Holly
    Neugebauer, Romain S.
    Gosiker, Bennett
    Thomas, Tainayah W.
    Karter, Andrew J.
    Gilliam, Lisa K.
    Oshiro, Caryn
    An, Jaejin
    Simonson, Gregg
    Cassidy-Bushrow, Andrea E.
    Dombrowski, Sarah
    Nolan, Margaret
    O'Connor, Patrick J.
    Schmittdiel, Julie A.
    LANCET REGIONAL HEALTH-AMERICAS, 2024, 34
  • [25] Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?
    Lee, Blaire
    Holstein-Rathlou, Niels-Henrik
    Sosnovtseva, Olga
    Sorensen, Charlotte M.
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2023, 325 (01): : C243 - C256
  • [26] Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
    Natali, Andrea
    Nesti, Lorenzo
    Trico, Domenico
    Ferrannini, Ele
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [27] GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus
    Dahiya, Lalita
    Kaur, Ramandeep
    Kumar, Rajiv
    Kumar, Manoj
    Palta, Kezia
    CURRENT DIABETES REVIEWS, 2020, 16 (04) : 279 - 292
  • [28] Effect of 3-month therapy with SGLT-2 inhibitors and GLP-1 agonists on ambulatory blood pressure in patients with type 2 diabetes mellitus
    Papazafiropoulou, Athanasia
    Papantoniou, Styliani
    Rallatou, Maria
    Melidonis, Andreas
    Antonopoulos, Stavros
    SCIENTIFIC CHRONICLES, 2020, 25 (03) : 528 - 536
  • [29] Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence
    Sammour, Yasser
    Nassif, Michael
    Magwire, Melissa
    Thomas, Merrill
    Fendler, Timothy
    Khumri, Taiyeb
    Sperry, Brett W.
    O'Keefe, James
    Kosiborod, Mikhail
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (06) : 426 - 429
  • [30] Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
    Georgianos, Panagiotis I.
    Vaios, Vasilios
    Roumeliotis, Stefanos
    Leivaditis, Konstantinos
    Eleftheriadis, Theodoros
    Liakopoulos, Vassilios
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):
12345